Archive for the ‘Cervical Cancer / HPV Vaccine’ Category
Tuesday, April 1st, 2008
Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has begun a pivotal U.S. clinical trial of its investigational APTIMA(R) assay to detect human papillomavirus (HPV), which causes cervical cancer. "Starting this highly complex, multi-center study was an important goal for Gen-Probe in early 2008," said ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Saturday, March 29th, 2008
A recent CDC study that found that about 25% of female teenagers ages 14 to 19 have at least one common sexually transmitted infection should "reinvigorate" the debate over requiring human papillomavirus vaccines for school admission, a Washington Post editorial says. Although more than 20 states and Washington, D.C., recently ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
A recent CDC study that found that about 25% of female teenagers ages 14 to 19 have at least one common sexually transmitted infection should "reinvigorate" the debate over requiring human papillomavirus vaccines for school admission, a Washington Post editorial says. Although more than 20 states and Washington, D.C., recently ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. Preliminary evaluation of biological samples collected from the study's ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
FDA has granted priority review status to Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, Reuters reports. The designation means that an FDA decision could come within six months, according to Reuters. currently is approved by the ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted, and designated for priority review, the supplemental Biologics License Application (sBLA) for GARDASIL® [Human Papillomavirus Quadrivalent] (Types 6, 11, 16, 18) Vaccine, Recombinant] for the potential use in women aged 27 through 45. A ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 28th, 2008
The virus responsible for most cases of cervical cancer has a serious weakness which may provide hope for new treatments for the disease.Human Papillomavirus (HPV), a virus which causes several types of cancer but is particularly associated with cervical cancer, has developed clever ways of hiding in the body, but ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Wednesday, March 26th, 2008
In a new collaborative study, the BC Cancer Agency, an agency of the Provincial Health Services Authority (PHSA), is trying to determine if a test for Human Papilloma Virus (HPV) can replace the standard Pap test as the primary method of cervical cancer screening, allowing women to be screened more ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 24th, 2008
FDA has granted priority review status to Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, Reuters reports. The designation means that an FDA decision could come within six months, according to Reuters. currently is approved by the ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 24th, 2008
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted, and designated for priority review, the supplemental Biologics License Application (sBLA) for GARDASIL® [Human Papillomavirus Quadrivalent] (Types 6, 11, 16, 18) Vaccine, Recombinant] for the potential use in women aged 27 through 45. A ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Friday, March 21st, 2008
The virus responsible for most cases of cervical cancer has a serious weakness which may provide hope for new treatments for the disease.Human Papillomavirus (HPV), a virus which causes several types of cancer but is particularly associated with cervical cancer, has developed clever ways of hiding in the body, but ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Tuesday, March 18th, 2008
Government should set a timeline and framework for ensuring cervical cancer screening and human papillomavirus immunisation work together to further reduce cervical cancer burden in Australia, according to a report released today (18/3) by The Cancer Council Australia. Releasing the recommendations of a "roundtable" meeting of Australian experts, the Cancer ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 17th, 2008
Third Wave Technologies Inc. (NASDAQ: TWTI) announced that the company achieved all primary clinical endpoints in the clinical trial for its human papillomavirus (HPV) tests. The company expects to submit the trial results to the U.S. Food and Drug Administration for both its high-risk and 16/18 genotyping products in April. ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 17th, 2008
Nventa Biopharmaceuticals Corporation (TSX: NVN) announced that the Company has completed enrollment and initiated dosing of the fourth and final cohort of patients in its Phase 1 dose escalation trial. This study examines the safety of its lead candidate, new HspE7 (HspE7 + Poly-ICLC, a toll-like receptor-3, or TLR3 ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »
Monday, March 17th, 2008
It has been almost two years since the first vaccine to prevent cervical cancer was approved for regular clinical use, and the Society of Gynecologic Oncologists (SGO), the professional association for experts in women's cancer, will take a critical look at HPV and Cervical Cancer as well as ...
Posted in Cervical Cancer / HPV Vaccine | No Comments »